CY1113395T1 - Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη - Google Patents

Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη

Info

Publication number
CY1113395T1
CY1113395T1 CY20121101126T CY121101126T CY1113395T1 CY 1113395 T1 CY1113395 T1 CY 1113395T1 CY 20121101126 T CY20121101126 T CY 20121101126T CY 121101126 T CY121101126 T CY 121101126T CY 1113395 T1 CY1113395 T1 CY 1113395T1
Authority
CY
Cyprus
Prior art keywords
sulfamidi
pharmaceutical composition
composition containing
stable pharmaceutical
containing pyrimidine
Prior art date
Application number
CY20121101126T
Other languages
Greek (el)
English (en)
Inventor
Charles Tokunbo Adesuyi
Lovelace Holman
Olivier Lambert
Bruce Hamilton Lithgow
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37865339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113395(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of CY1113395T1 publication Critical patent/CY1113395T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20121101126T 2005-09-12 2012-11-21 Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη CY1113395T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005009775 2005-09-12
EP06809280A EP1928409B1 (en) 2005-09-12 2006-09-11 Stable pharmaceutical composition comprising a pyrimidine-sulfamide

Publications (1)

Publication Number Publication Date
CY1113395T1 true CY1113395T1 (el) 2016-06-22

Family

ID=37865339

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101126T CY1113395T1 (el) 2005-09-12 2012-11-21 Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη

Country Status (23)

Country Link
US (6) US20080233188A1 (enExample)
EP (2) EP1928409B1 (enExample)
JP (2) JP4955685B2 (enExample)
KR (1) KR101313395B1 (enExample)
CN (1) CN101262847B (enExample)
AU (1) AU2006290309B2 (enExample)
BR (1) BRPI0615898B8 (enExample)
CA (1) CA2621273C (enExample)
CY (1) CY1113395T1 (enExample)
DK (1) DK1928409T3 (enExample)
ES (1) ES2393117T3 (enExample)
HR (1) HRP20120957T1 (enExample)
IL (1) IL190072A (enExample)
MY (1) MY151003A (enExample)
NO (1) NO341325B1 (enExample)
NZ (1) NZ567188A (enExample)
PL (1) PL1928409T3 (enExample)
PT (1) PT1928409E (enExample)
RU (1) RU2424805C2 (enExample)
SI (1) SI1928409T1 (enExample)
TW (1) TWI323661B (enExample)
WO (1) WO2007031933A2 (enExample)
ZA (1) ZA200802947B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313395B1 (ko) 2005-09-12 2013-10-02 액테리온 파마슈티칼 리미티드 피리미딘-설파마이드를 함유하는 안정한 제약학적 조성물
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
MX2010001837A (es) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
KR20100132489A (ko) * 2008-02-20 2010-12-17 액테리온 파마슈티칼 리미티드 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합
HUE047767T2 (hu) * 2008-08-13 2020-05-28 Actelion Pharmaceuticals Ltd Macitentánt tartalmazó terápiás készítmények
ES2543280T3 (es) * 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
US10071059B2 (en) 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
IT1403248B1 (it) * 2010-11-12 2013-10-17 Scharper Therapeutics Srl Composizione per il trattamento di disfunzioni degli apparati fonatorio ed olfattorio
TW201309298A (zh) 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd 治療惡性神經膠質瘤之醫藥組合物
DE14721256T1 (de) * 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
NZ714963A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
WO2014198178A1 (zh) * 2013-06-14 2014-12-18 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
US20170158645A1 (en) * 2014-07-15 2017-06-08 Olon S.P.A. Amorphous form and new crystalline forms of macitentan
DK3172209T3 (da) 2014-07-25 2021-02-22 Novartis Ag Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid
CN105388244B (zh) * 2015-12-10 2017-03-08 合肥久诺医药科技有限公司 一种马西替坦有关物质的高效液相色谱分析方法
WO2018153925A1 (en) 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
SI3897646T1 (sl) 2018-12-21 2024-08-30 ACTELION PHARMACEUTICALS lTD, Makitentan za zdravljenje pljučne arterijske hipertenzije
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
RS66002B1 (sr) 2019-05-22 2024-10-31 Wuxi Biocity Biopharmaceutics Co Ltd Kristalni oblik jedinjenja pirimidin sulfonamida i postupak za njegovu pripremu
AU2020309223B2 (en) 2019-07-05 2025-05-29 TECNIMEDE - Sociedade Técnico-Medicinal, S.A Compressed macitentan compositions, methods and uses thereof
TW202133851A (zh) 2019-11-29 2021-09-16 瑞士商艾克泰聯製藥有限公司 治療肺動脈高血壓之方法
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
TW202317119A (zh) * 2021-06-11 2023-05-01 瑞士商艾克泰聯製藥有限公司 用於口服投予之分散錠
CN117835971A (zh) 2021-08-25 2024-04-05 巴斯夫欧洲公司 直接压片用辅料组合物
WO2023038600A1 (en) * 2021-09-07 2023-03-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A capsule formulation comprising macitentan
EP4154873A1 (en) 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
ATE201202T1 (de) 1995-12-20 2001-06-15 Yamanouchi Pharma Co Ltd Arylethensulfonamid-derivate und diese enthaltende medikamente
JPH103525A (ja) 1996-06-14 1998-01-06 Dainippon Printing Co Ltd Icカード、命令コード格納方法及び命令コード実行方法
AR017426A1 (es) 1997-12-08 2001-09-05 Smithkline Beecham Corp Sal de monoargininilo del acido (e)-3-[1-n-butil-5-[2-(2-carboxifenil)metoxi-4-clorofenil]-1h-pirazol-4-il]-2-[(5-metoxi-2,3-dihidrobenzofuran-6-il)metil]-prop-2-enoico, composicion farmaceutica que la contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion
ATE219658T1 (de) 1998-03-06 2002-07-15 Eurand Int Schnell zerfallende tablette
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20040062803A1 (en) * 1999-12-22 2004-04-01 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
CZ20022293A3 (cs) * 1999-12-31 2003-04-16 Texas Biotechnology Corporation Sulfonamidy a jejich deriváty, které upravují aktivitu endothelinu
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
HUP0301802A3 (en) 2000-06-28 2009-04-28 Teva Pharma Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
US7125565B2 (en) 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
CN1486302A (zh) 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
KR100819668B1 (ko) * 2000-12-18 2008-04-04 액테리온 파마슈티칼 리미티드 신규한 피리미딘-설퍼아마이드
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
JP3930290B2 (ja) 2001-09-12 2007-06-13 富士フイルム株式会社 熱現像感光材料及びそれを用いた熱現像方法
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
JP2006502083A (ja) * 2002-01-07 2006-01-19 ファルマシア コーポレイション 高められた溶解速度を有する薬物混合物
MXPA04007737A (es) 2002-02-11 2004-10-15 Pfizer Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4.
IL163642A0 (en) * 2002-02-26 2005-12-18 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
GB0204771D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
WO2004067008A1 (ja) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited 受容体作動薬
MXPA05009098A (es) 2003-02-25 2005-11-17 Lilly Co Eli Clorhidrato de 1- (4-(2 -piperidiniletoxifenoxi) -2-(4-metansulfonilfenil) -6-hidroxinaftaleno cristalino no solvatado.
EP1697382A4 (en) 2003-12-10 2008-11-05 Activbiotics Inc ANALOGUES OF RIFAMYCIN AND USES THEREOF
US7094081B1 (en) * 2005-03-24 2006-08-22 Delphi Technologies, Inc. Electrical connector assembly
KR101313395B1 (ko) 2005-09-12 2013-10-02 액테리온 파마슈티칼 리미티드 피리미딘-설파마이드를 함유하는 안정한 제약학적 조성물
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
KR20100132489A (ko) 2008-02-20 2010-12-17 액테리온 파마슈티칼 리미티드 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합
HUE047767T2 (hu) 2008-08-13 2020-05-28 Actelion Pharmaceuticals Ltd Macitentánt tartalmazó terápiás készítmények
TW201309298A (zh) 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd 治療惡性神經膠質瘤之醫藥組合物

Also Published As

Publication number Publication date
BRPI0615898B1 (pt) 2020-02-18
US10117870B2 (en) 2018-11-06
US20180263980A1 (en) 2018-09-20
MY151003A (en) 2014-03-31
CA2621273C (en) 2014-07-29
TWI323661B (en) 2010-04-21
CA2621273A1 (en) 2007-03-22
NO341325B1 (no) 2017-10-16
US20080233188A1 (en) 2008-09-25
RU2008113869A (ru) 2009-10-20
TW200803860A (en) 2008-01-16
US20130190336A1 (en) 2013-07-25
US9265762B2 (en) 2016-02-23
JP4955685B2 (ja) 2012-06-20
JP2009519893A (ja) 2009-05-21
NZ567188A (en) 2011-04-29
WO2007031933A3 (en) 2007-10-18
US20210186966A1 (en) 2021-06-24
SI1928409T1 (sl) 2012-12-31
PL1928409T3 (pl) 2013-02-28
HK1121950A1 (en) 2009-05-08
WO2007031933A2 (en) 2007-03-22
NO20081724L (no) 2008-04-09
AU2006290309B2 (en) 2012-04-05
RU2424805C2 (ru) 2011-07-27
JP5054061B2 (ja) 2012-10-24
EP2292209A2 (en) 2011-03-09
US10946015B2 (en) 2021-03-16
US20160136163A1 (en) 2016-05-19
DK1928409T3 (da) 2012-11-05
PT1928409E (pt) 2012-11-27
EP2292209A3 (en) 2011-05-04
IL190072A (en) 2013-08-29
US11648249B2 (en) 2023-05-16
US20100004274A1 (en) 2010-01-07
EP1928409B1 (en) 2012-09-12
AU2006290309A1 (en) 2007-03-22
CN101262847B (zh) 2010-11-24
ZA200802947B (en) 2009-12-30
HRP20120957T1 (hr) 2012-12-31
IL190072A0 (en) 2008-08-07
ES2393117T3 (es) 2012-12-18
JP2009235073A (ja) 2009-10-15
CN101262847A (zh) 2008-09-10
US8367685B2 (en) 2013-02-05
EP1928409A2 (en) 2008-06-11
KR20080055897A (ko) 2008-06-19
KR101313395B1 (ko) 2013-10-02
BRPI0615898B8 (pt) 2021-05-25
BRPI0615898A2 (pt) 2011-05-31

Similar Documents

Publication Publication Date Title
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
EA200970156A1 (ru) Пиридизиноновые производные
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
UA94833C2 (en) Substituted bicyclolactams
EA200702497A1 (ru) Замещенные арилпиразолы для применения против паразитов
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CY1112019T1 (el) Αγωνιστες υποδοχεων νιασινης, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι θεραπειας
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
SE0400284D0 (sv) Novel compounds
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
TW200612936A (en) Indole derivatives
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
MX2009008028A (es) Agentes antiparasitarios.
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201290229A1 (ru) Производные спиролактама и их применение
EA201000703A1 (ru) Производные пиразола в качестве ингибиторов 5-lo
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
EA200901030A1 (ru) Антагонист хроменового рецептора s1p1
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина